|
|
|
|
|
Fetal
Medicine
Foundation
|
|
|
|
|
Aims
|
|
|
|
|
|
|
|
 |
|
|
|
Meaning of Nuchal Translucency.
Congenital anomaly and chromosomal abnormality.
Diagnosis/screening: advantages and disadvantages. | |
|
|
|
|
Amniocentesis/CVS is offered in Italy at the age 35, while in France at 38. In U.K. age is not criteria of choice: why? | |
|
|
|
|
NT should be performed between 11 weeks+ 4 days and 13 weeks + 5 days before invasive procevures (CVS, amniocentesis). | |
|
|
|
|
How to carry out the Nuchal Translucency screening.
Reference. | |
|
|
|
|
The importance of quality control.
Italian Specialists accredited for Nuchal Translucency. | |
|
|
|
|
The problem of increased NT.
The II level assessment. | |
Created by Dr. Claudio Lombardi, Vimercate (MI) Italy - ph.+390396852226 email:fetalmedicine@mac.com-Last upd: 4/11/2011
|
| |
